Merck, Sanofi join Novartis’ 10-year quest to improve clinical trial diversity as historically Black colleges pitch in
Merck and Sanofi are joining Novartis’ 10-year commitment to increasing diversity in clinical research through a collaboration with historically Black colleges and universities.
With new grants worth $17.7 million, the so-called Beacon of Hope program now totals more than $50 million in commitments over the decade-long project, which aims to address health disparities and enhance diversity, equity and inclusion across drug research and development, particularly in clinical trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.